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We describe a case series of 35 Ebola virus disease (EVD) survivors during the epidemic in West 
Africa who had neurologic and accompanying psychiatric sequelae. Survivors meeting neurologic 
criteria were invited from a cohort of 361 EVD survivors to attend a preliminary clinic. Those whose 
severe neurologic features were documented in the preliminary clinic were referred for neurology 
specialist evaluation, ophthalmology examination, and psychiatric assessment. Of 35 survivors with 
neurologic sequelae, 13 had migraine headache, 2 stroke, 2 peripheral sensory neuropathy, and 2 
peripheral nerve lesions. Of brain computed tomography scans of 17 patients, 3 showed cerebral 
and/or cerebellar atrophy and 2 confirmed strokes. Sixteen patients required mental health followup; 
psychiatric disorders were diagnosed in 5. The 10 patients who experienced greatest disability had 
co-existing physical and mental health conditions. EVD survivors may have ongoing central and 
peripheral nervous system disorders, including previously unrecognized migraine headaches and 
stroke. 
The 2014–2016 West Africa Ebola virus disease (EVD) epidemic resulted in an estimated 
3,956 deaths and 10,168 survivors in Sierra Leone (1). Provision of high-quality specialty 
services for survivors offers an opportunity to improve our understanding of the debilitating 
post-EVD sequelae. 
Central nervous system (CNS) viral invasion by EVD had been suspected but unproven 
until the West Africa EVD epidemic. In this outbreak, individual case-patient reports describe 
clinical features of meningoencephalitis or meningitis during and after acute Ebola virus (EBOV) 
infection, accompanied by EBOV PCR results in nonbloodstained cerebrospinal fluid samples 
(CSF) (2–6). Cranial imaging of 3 encephalitic patients documented changes consistent with 
cerebral atrophy (3), meningoencephalitis (4), and areas of diffusion restriction suggesting 
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ischemia (4,5). Nonhuman primate EVD models and human Marburg neuropathology found 
EBOV-immunoreactive glial nodules and perivascular infiltrates (7–9) and evidence of 
choriomeningioencephalitis (10). In addition, a novel retinal lesion in Ebola survivors that 
appears to follow ganglion cell axons as they exit the optic nerve has been described (11). 
Combined with the observation that human CSF can be EBOV PCR–positive after plasma 
testing shows negative results (3,4), these observations raise the possibility that infected CNS 
cells may have a role in persistent or recurrent neurologic disease. 
Observational studies of survivors report a broad range of neuropsychiatric symptoms 
(12–14), including increased fatigue, diminished work capacity, and sleep disturbance (15,16). 
Psychosocial distress caused by bereavement, stress, and stigma and formal psychiatric 
diagnoses of depression, anxiety and adjustment disorder have been reported (17–21). 
To define the full spectrum of characteristics and severity of neurologic and psychiatric 
disease, we investigated neurologic sequelae in patients with neurologic symptoms by providing 
specialist neurologic evaluation, psychiatric and disability assessment, and brain computed 
tomography (CT) imaging and retinal imaging to an EVD survivor cohort. Our additional 
objective was to describe psychiatric, disability, and ophthalmic outcomes for survivors with 
neurologic sequelae. 
Materials and Methods 
We completed this prospective observational study during February 4–May 10, 2016. 
Patients eligible for inclusion were >12 years of age, had complete clinical records, and attended 
the 34 Military Hospital (34MH) Ebola Survivors Clinic, Freetown, Sierra Leone. All patients 
provided Ebola survivor discharge certificates as proof of identity at initial enrolment in the 
34MH cohort and on attending the preliminary clinic. Furthermore, staff at the 34MH clinic had 
provided care in the 34MH emergency treatment unit (ETU) and could certify the validity of 
survivors. The preliminary clinic took place at the 34MH Ebola Survivors clinic and the 
specialist clinics at Connaught Hospital, Freetown, Sierra Leone. 
Patients were invited to the preliminary clinic on the basis of having reported >1 major or 
>2 minor symptoms (Table 1). These criteria aimed to maximize sensitivity for neurologic and 
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psychiatric conditions. In addition, clinic staff invited additional patients suspected of having 
neurologic symptoms. 
In the preliminary clinic, an intern physician, supported by trained nursing staff, obtained 
informed written consent to publish clinical data and images and administered an initial 
questionnaire. Further history and examination, including full neurologic examination, was 
accomplished by 2 physicians who used structured data recording forms. Patients with prominent 
or disabling symptoms of neurologic origin that required referral to the joint neurologic and 
psychiatric clinic were defined as having severe neurologic features. Patients with neurologic 
sequelae who did not warrant referral became a no severe neurologic features group. Laboratory 
tests, including lumbar puncture and brain CT, were available according to clinical need. Patients 
who had >2 psychiatric symptoms were referred for psychiatric assessment. 
In the specialist clinic, full neurologic history and examination was performed 
individually or jointly by 2 consultant neurologists. Psychiatric assessment was performed onsite 
by 2 higher-level psychiatry trainees. Psychiatric assessment included Mini International 
Neuropsychiatric Interview (MINI-plus) and Mini Mental State Examination (MMSE; Mapi 
Research Trust PROVIDE, Lyon, France) and the World Health Organization Disability 
Assessment Schedule 2.0 (WHO-DAS 2.0; http://www.who.int/classifications/icf/whodasii/en/). 
The WHO-DAS 2.0 is a cross-cultural and validated tool providing a score that is compared to 
population percentile values (22). Although no cognitive or psychiatric assessment tools have 
been validated for the Sierra Leone population, the MMSE is frequently used by staff in the 
Connaught mental health clinic. Patient follow-up occurred at a second neurology clinic, in their 
local mental health clinic, and by telephone. 
Patients underwent enhanced axial CT imaging of the brain, and scans were reviewed by 
a consultant neuroradiologist by using Mango software (http://ric.uthscsa.edu/mango/). All 
patients reviewed by specialists were invited for ophthalmology examination, including retinal 
imaging. Images were reported by ophthalmologists. 
Statistical Analysis 
We collected data on paper forms structured for clinical use, entered it into Microsoft 
Excel 2011 (Microsoft, Redmond, WA, USA), and edited it for missing information. We 
Publisher: CDC; Journal: Emerging Infectious Diseases 
Article Type: Synopsis; Volume: 24; Issue: 8; Year: 2018; Article ID: 17-1367 
DOI: 10.3201/eid2408.171367; TOC Head: Synopsis 
Page 5 of 19 
analyzed data by using Stata version 14.0 (StataCorp LLC, College Station, TX, USA). For 
sample sizes ≥35, we calculated 95% CIs for proportions by using an exact binomial method. 
Unadjusted odds ratios were calculated for binary and ordinal variables. We used the Wilcoxon 
rank sum test for comparison of continuous data and the Fisher exact test for categorical data. 
For multivariable logistic regression of factors associated with attending or not attending the 
preliminary clinic, we used a predetermined model with age (linear term), sex, and presence of 
major or minor criteria as explanatory variables. EBOV PCR cycle threshold (Ct) (a figure 
inversely representative of plasma viral load, with >40 cycles used as a negative cutoff value) 
was not included in the regression models because different laboratories used different 
thresholds. 
This study was reviewed in accordance with University of Liverpool human subjects 
review procedures and determined to be a nonresearch public health response activity. Ethics 
approval was confirmed in writing from the Sierra Leone Ethics and Scientific Review 
Committee. All data collection instruments were stored in a secured location, accessible only by 
study staff. Personal identifiers were removed from the database before analysis. 
Results 
Of 361 patients, 5 patients were excluded because clinical data were incomplete and 22 
because they were <12 years of age. Of the 334 included patients, 161 (49.7%, 95% CI 44.1%–
55.3%) were female and 163 (50.3%, 95% CI 44.7%–55.9%) male; sex was not recorded for 10 
patients. Median patient age was 28 (IQR 23.0–37.0) years. A total of 111 (33.2%, 95% CI 
28.2%–38.6%) patients were eligible for the preliminary clinic; 32 (9.6%, 95% CI 6.6%–13.3%) 
patients had 1 major criteria, 74 (22.2%, CI 95% 17.8%–27.0%) had >2 minor criteria, and 12 
(3.3%, 95% CI 1.7%–5.8%) were referred by clinic staff. A total of 40 (12.0%, 95% CI 8.7%–
15.9%) patients attended the clinic (Figure 1). Among the 334 patients evaluated, the most 
common symptoms were headache (167, 50.0%, 95% CI 44.5%–55.5%), loss of appetite (33, 
9.9%, 95% CI 6.9%–13.6%), and generalized weakness (22, 6.6%, 95% CI 4.2%–9.8%) (Figure 
2). Female patients were more likely to be invited to the preliminary clinic than were male 
patients (OR 2.01, 95% CI 1.22–3.32; p = 0.03) (online Technical Appendix Table 1, 
https://wwwnc.cdc.gov/EID/article/24/8/17-1367-Techapp1.pdf). In those invited to the 
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preliminary clinic, on multivariable analysis, the presence of minor criteria was associated with 
nonattendance (OR 0.10, 95% CI 0.03–0.56; p = 0.005) (online Technical Appendix Table 2). 
Of the 40 patients attending the preliminary clinic, 26 (65%, 95% CI 48.3%–79.3%) were 
female, and the median age was 32 (IQR 25–43) years. Patients were seen in the clinic a median 
of 430 (IQR 401–473) days after the first positive diagnostic results. At the time of preliminary 
clinic, 35 (87.5%, 95% CI 73.2%–95.8%) had neurologic or psychiatric symptoms (Table 2). 
None reported any substantial medical history of neurologic or mental health disorder. Of the 40 
patients, 19 (47.5%, 95% CI 31.5%–63.9%) were defined as having severe neurologic signs and 
symptoms and were offered referral to the joint neurology and psychiatric clinic, brain CT, and 
retinal imaging. An additional 5 patients were referred for psychiatric review only. We found no 
significant difference in demographic or acute EVD features between patients with and without 
severe neurologic features (Table 3). A greater proportion of patients with severe neurologic 
symptoms were unconscious during any point in admission to the ETU, but this association was 
weak (OR 3.32, 95% CI 0.79–15.40; p = 0.11). Due to data sparsity, multivariable analysis was 
not performed. 
Clinical Features 
In the preliminary clinic, a new or different headache since acute EVD admission was 
reported by 30 (75.0%, 95% CI 58.8%–87.3%) patients; female:male ratio was 2:1. Of those 
with headache, 14 (46.6%, 95% CI 38.3%–65.7%) had undifferentiated headache, 13 (43.3%, 
95% CI 25.5%–62.6%) migraine, and  3 (10.0%, 95% CI 2.1%–26.5%) tension-type headaches 
(online Technical Appendix Table 3). Five patients who had migraine headaches were prescribed 
oral propranolol (20 mg 1/d), in keeping with WHO guidance on survivor care (23); 4 returned 
for follow-up 1 month after treatment and reported symptomatic improvement. 
One male and 1 female survivor, both age 42, had evidence of stroke; symptom onset 
occurred at the time of acute EVD. These patients had the highest disability scores (WHO 
Disability Assessment Schedule 2.0 scores 89.58 and 33.33, respectively) and met criteria for a 
mental health disorder (see Case Study 1). Given the major vessel territory distribution on CT, 
these strokes are suspected to be mature ischemic infarcts. 
Publisher: CDC; Journal: Emerging Infectious Diseases 
Article Type: Synopsis; Volume: 24; Issue: 8; Year: 2018; Article ID: 17-1367 
DOI: 10.3201/eid2408.171367; TOC Head: Synopsis 
Page 7 of 19 
Two survivors had peripheral sensory neuropathy and 2 focal peripheral nerve lesions. 
Brachial plexopathy was diagnosed in a 27-year-old woman during acute EVD. Neuropathy 
screening of the patient for treatable causes was negative, and she was referred for 
physiotherapy. Asymmetric glove and stocking peripheral sensory neuropathy was diagnosed in 
a 35-year-old man, occurring since ETU discharge. Diabetes and major depressive disorder were 
diagnosed, and he was referred to the diabetes and mental health clinic. Other reported 
neurologic symptoms in the cohort included 3 cases of tinnitus, 2 cases of tremor, and 1 case of 
asymmetric lower limb atrophy with weakness of unknown etiology. Of the 19 patients who 
attended the specialist clinic, 12 were reviewed 1 year later, in June 2017; 10 reported 
improvement of symptoms, 1 reported no changes, and 1 reported a new headache. After this, 
case-study patient 1 died. 
Psychiatric symptoms were common among 21 (52.5%, 95% CI 36.1%–68.4%) survivors 
describing difficulty sleeping; 12 (30.0%, 95% CI 16.5%–46.5%) described depressive 
symptoms and 11/40 (27.5%, 95% CI 14.6%–43.9%) anxiety symptoms (online Technical 
Appendix Table 4). Of 24 (60.0%, 95% CI 43.3%–75.1%) survivors referred for psychiatric 
review, 19 (47.5%, 95% CI 31.5–63.8%) attended the clinic. Of those, 16 (63.3%) required 
referral for local mental health follow-up, of whom 5 met criteria for mental disorder (2 
generalized anxiety disorder; and 3 major depressive disorder). The most common reasons for 
mental health referral were stigma, grief, and loss of employment. Of the 19 patients whoa 
attended the psychiatric clinic, median MMSE score was 93.3% (IQR 87.7%–96.3%). No patient 
reported suicidal ideation. 
Among 19 survivors assessed for disability, the median WHO-DAS 2.0 score was 8.3% 
(IQR 3.1%–13.5%) corresponding to the 69th percentile of the normative population. The 9 
patients who had a disability score >10 (corresponding to scores found in <27.65% of the 
normative population) included all survivors affected by mental health disorders, stroke, and 
peripheral neuropathies for which disabilities were assessed. The most severe case of disability is 
described in Case Study 2. 
Of 17 patients who underwent brain CT, abnormalities were shown for 7. Three scans 
showed evidence of cerebral or cerebellar atrophy that was atypical for patient age (Figure 3, 
panel A), 2 confirmed the clinical assessment of stroke (Figure 3, panel B), and 2 showed 
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evidence of calcification, differentials of which include previous focal hemorrhage occurring >1 
year before the scan. 
Of the 40 survivors evaluated at the prelimnary clinic, 12 described eye pain (30.0%, 
95% CI 16.6%–46.5%) and 8 (20.0%, 95% CI 9.1%–35.6%) described partial visual loss. Of 17 
patients who attended the ophthalmology specialist clinic for examination, and wide field-
scanning laser ophthalmoscope imaging, 3 (15.8%) had Ebola retinal lesions (Figure 3, panels C, 
D [24]) (11). One survivor had unilateral retinal detachment, 1 intermediate uveitis, and 1 
posterior subcapsular cataract suggestive of previous uveitis. 
Case Studies 
Case Study 1—Patient No. 25 
Patient no. 25 was a previously fit and well 41-year-old male soldier who had an 
uncomplicated 8-day acute admission to a hospital for treatment of EVD; 3 days after discharge, 
he had sudden onset of left-sided weakness and dysphasia. In the neurology clinic, 545 days after 
his admission for acute illness, examination was consistent with a right upper motor neuron 
lesion. His MMSE was 26/27 and WHO-DAS 2.0 score 89.58, conforming to significant 
disability. He exhibited a pervasive low mood, anhedonia, feelings of worthlessness, guilt, 
frustration, and hopelessness regarding the future because of disability. His CT results showed 
extensive gliosis within the left middle cerebral artery territory, in keeping with mature infarct 
(Figure 3, panel B.). Retinal imaging showed bilateral Ebola retinal lesions (Figure 3, panels C,  
D [24]). Stroke and major depressive disorder were diagnosed. He was referred for 
physiotherapy, which resulted in marked improvement in symptoms, and received mental health 
clinic follow-up. Approximately 1 year after the intial clinic visit, the patient had an 
undifferentiated feve;, serum from a blood sample tested EBOV PCR negative, but he died 
several days later. 
Case Study 2—Patient No. 37 
A 12-year-old girl who had a normal developmental history had a Ct of 27.9 at hospital 
admission for EVD; she improved with treatment and became serum EBOV PCR negative on 
days 15 and 17. On day 20, her consciousness level gradually declined and fever recurred; she 
then had recurrent seizures for 48 hours that were partially controlled by administration of 
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phenytoin and diazepam. Her consciousness level gradually improved over the next 4 weeks to 
spontaneously alert but confused. At the preliminary clinic, 454 days after acute admission, she 
was blind and had substantial hearing loss and severe cognitive impairment. She was doubly 
incontinent and required 24-hour care for all activities of daily living. Her CT results showed 
disproportionate parietal and temporal lobe atrophy (Figure 3, panel C [24]). CSF test results 
were EBOV negative; results of a specialist’s ophthalmology review were unremarkable. 
Planning for her complex care needs required multiagency and multidisciplinary coordination to 
find an orphanage and provide resources and training to that facility to help manage her needs. 
She was unable to attend the specialist neurology clinic because of the remote location of her 
orphanage. Follow-up visits to the orphanage from the medical, psychiatric, and therapies team 
found no major functional improvements. 
Discussion 
Previous studies have outlined the frequency of a variety of neurologic symptoms in 
EVD survivors (13). Our specialist case series from the 34MH survivor’s cohort confirms the 
presence of central and peripheral nervous system disorders and found these to be associated 
with a broad range of disability. The most frequent neurologic diagnosis was migraine 
headaches; the next most common, respectively, were stroke, peripheral sensory neuropathy, and 
focal peripheral nerve lesions. Most survivors had co-occurring mental health problems, the most 
frequent psychiatric diagnoses being major depressive disorder and generalized anxiety disorder. 
The most severely affected patients had symptoms of blindness, deafness, focal weakness, and 
cognitive dysfunction, associated with disability and mental illness. 
The diagnosis of migraine headache found in 13 case-patients was characterized by 
intermittent, throbbing headaches associated with photophobia, phonophobia, and, in some cases, 
vomiting. These symptoms were either new or substantially worse after acute EVD. In a small 
group, treatment with propranolol  according to WHO guidelines (23) led to subjective 
improvement. To date, headaches in the EVD survivor population have not been well described; 
a small group of survivors was noted to have unilateral and throbbing headaches (19), although 
frequency from the 2014–2016 West Africa Ebola disease outbreak ranges from 22%–68% 
(14,19,20,25), In the only case–control study in which 90% of survivors reported headache, a 
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high prevalence of 75% in the control population meant this finding was not significant (16). A 
recent meta-analysis reported a community migraine prevalence of 5.6% (95% CI 4.6%–6.7%) 
in community-based studies in Africa (26). Because our preliminary clinic selection criteria 
required patients with headache to have >1 associated symptom, our headache findings and 
prevalence may not be representative of the survivor population. Potential mechanisms for 
migraine headache in EVD survivors may include autonomic dysregulation (27), changes in 
tryptophan-serotonin levels after infection (27), or ongoing neuroinflammation, as seen in HIV 
infection (29). With limited diagnostic methods, we are unable to determine specific etiologies of 
all neuropathy or suspected myopathy cases; however, diabetic neuropathy, entrapment 
neuropathy, or critical illness polyneuropathy with slow recovery are potential causes. 
Radiologic imaging showed sequelae of focal or generalized atrophy or stroke in some 
patients. As previously reported (5,12), we found substantial cerebral atrophy in 2 patients and 
isolated cerebellar atrophy in 1 other survivor. One patient had a reported case of late onset 
encephalitis (3), and 1 patient’s imaging correlated with substantial cognitive deficit, cortical 
blindness, and hearing impairment (see Case Study 2). Although it is possible the atrophy was 
related to birth complications, nutritional deficiency, or childhood illness, the prominent parietal 
and temporal lobe atrophy of this adolescent case-patient resembles radiologic findings in 
subacute sclerosing panencephalitis, a chronic CNS infection caused by defective measles virus, 
raising the possibility of similar CNS mechanisms of EVD and measles or persistent CNS 
infection (30). Cerebral CT images of 2 stroke case-patients, whose neurologic symptom onset 
occurred during acute EVD, were consistent with ischemic stroke. Suspected stroke during acute 
EVD has been reported (31), and thromboelastography, a measurement of thrombotic tendency, 
done during and after acute EVD illness, suggests a prothrombotic period in the immediate 
aftermath of EVD (32). 
In 3 (15.8%) of 19 patients in the severe neurologic features group, we observed the 
novel Ebola peripapillary retinal lesion, recently reported by Steptoe et al. (11), who described a 
similar prevalence (14.6%) among a wider survivor population. Although the most likely 
mechanism of CNS viral entry is from circulating infected cells, the presence of retinal 
peripapillary lesions, thought to represent virus spread along the retinal nerve fiber or ganglion 
cell axon layers, raises the possibility of CNS viral entry by neuronal spread. 
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The group of patients who had severe neurologic features generally had good results from 
adapted MMSE testing. For a patient who had a confirmed case of late-stage EVD encephalitis 
and initial neurocognitive impairment (3), assessment 1 year later showed good long-term 
recovery. This finding is encouraging and in keeping with 2 case reports of recovery from 
neurocognitive impairment (33). Despite onset being 1 year after acute disease and many patients 
having been initially referred to counsellors, 5 of 19 patients met criteria for psychiatric disorder; 
all 19 had concurrent physical symptoms, and 16 required mental health followup. As previously 
reported, survivors cited stigma, grief, and loss of employment as major stressors impeding 
recovery (17,34). 
A recent case–control study found survivors had major limitations of vision, cognition, 
affect, and, most markedly, mobility (35). In our study, we found 10 participants who reported 
high levels of disability and also had physical symptoms and co-occurring mental health issues. 
This clustering of physical and psychiatric sequelae and disability suggests a subset of patients 
most affected after acute EVD and with the greatest care needs. In the small number of self-
selecting case-patients on whom we followed up 18 months after the first neurology/psychiatric 
clinic, patients generally reported symptomatic improvement; however, improvement was not 
uniform. One case-patient subsequently died (patient no. 25; see Case Study 1), and another 
remains dependent for all activities of daily living (patient no. 37; see Case Study 2). 
Our study observed no association between severe neurologic conditions and admission 
Ct. To the contrary, among the 2 patients who had both prolonged periods of unconsciousness 
and cerebral atrophy on CT (patients no. 2 and 16), the neurologic episodes occurred late in the 
acute disease period, not at the time of peak viral load. Similarly, 2 case reports describe a 
prolonged meningoencephalitic stage of disease or meningoencephalitis occurring months after 
recovery (4,5). Of note, we found no cases of CNS infection recurrence. Unconsciousness during 
acute admission was more common among those who had severe neurologic symptoms on 
follow-up, although not to a significant degree, possibly caused by limited sample size (OR 3.32, 
CI 0.79–15.4; p = 0.11). Our preliminary group was selected on the basis of existing neurologic 
symptoms, which precludes a conclusion of causation and generalization to the wider EVD 
survivor population. 
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A major limitation of our case series is that we cannot firmly determine causation 
between our findings and the diagnosis of EVD beyond the temporal association. Furthermore, in 
keeping with other observational studies, a lack of reliable countrywide denominator data on 
conditions such as headache or stroke means we cannot assess the representativeness of our 
results. Validating our findings would require a large case–control study, in which our data could 
be used as a basis for study design. Retrospectively asking about acute symptoms incurs the 
possibility of recall bias; however, as acute records of the EBV outbreak clinics are sparse and 
linkage-challenging, this represented the most viable option. Despite our multiple attempts, the 
outcomes of 71/111 patients who were invited to but did not attend the preliminary clinic remain 
unknown. Although our analysis shows those with minor selection criteria were among those less 
likely to attend (p = 0.005), it is still possible we underrepresented patients who had more 
disabling conditions and were unable to access the service, as exemplified by the patient in Case 
Study 2. Further research should focus on a complete characterization of pathways of sequelae 
and persistent infection (36). 
Our case series, supported by brain CT imaging, confirms there are long-term neurologic 
sequelae in EVD survivors and a substantial proportion of these patients have ongoing mental 
health problems and disability. Often, these issues cluster together, and services should therefore 
seek out and support patients with a high burden of illness. If we wish to expand specialist 
services to the remaining EVD survivors and broader population, the only credible and 
sustainable option is to greatly increase support for in-country specialist training of doctors. 
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Table 1. Symptom-based criteria used to select patients for assessment in study of severe neurologic sequelae among Ebola virus 
disease survivors, Sierre Leone 
Major selection criteria Minor selection criteria 
Focal weakness Headache 
Tremor Insomnia 
Altered sensation Weakness 
Visual loss Loss of appetite 
Deafness Blurred vision 
Anxiety Dizziness 
Confusion  
Depression  
Psychosis  
Inability to balance  
Auditory disturbance  
Tinnitus  
Double vision  
*Patients were selected for inclusion in a preliminary clinic examination on 
the basis of >1 major or >2 minor criteria. 
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Table 2. Demographics, diagnoses, and management and outcome of 35 Ebola virus disease case-patients in whom neurologic and 
psychiatric conditions were diagnosed at preliminary and specialist neurology and psychiatric clinics, Sierre Leone* 
Patient 
no. 
Age, 
y/sex Diagnoses Management and outcome 
1 21/M Migraine headache, psychosocial issues MH follow-up 
2 47/M Resolved migraine headache, left retinal detachment Review at 1 y: no change in symptoms 
4 33/M Migraine headache DNA specialist clinic 
5 54/F Psychosocial issues, undifferentiated headache Referred to psychiatry for assessment but did not attend 
6 18/F Undifferentiated headache Referred return to general survivor’s clinic 
7 21/F Tension-type headache, major depressive disorder Local MH follow-up 
8 29/F Undifferentiated headache Referred return to general survivor’s clinic 
9 26/F Migraine headache Referred to MH for assessment but did not attend. 
Review at 1 y: improvement in symptoms 
10 27/F Right brachial plexus neuropathy Physiotherapy. Review at 1 y: substantial improvement 
in weakness 
11 42/F Right striatocapsular infarct, generalized anxiety disorder Physiotherapy, MH follow-up 
13 58/F Undifferentiated headache Referred return to general survivor’s clinic for 
nonneurologic other symptoms 
14 38/M Possible anterior uveitis, undifferentiated headache Ophthalmology referral 
15 49/F Tension-type headache Referred return to general survivor’s clinic for 
nonneurologic symptoms 
16 31/F Migraine headache Propranolol 20 mg/d; symptoms improved (unable to 
quantify) 
17 51/F Undifferentiated headache, peripheral sensory 
neuropathy 
Referred return to general survivor’s clinic for 
nonneurologic symptoms 
18 32/F Tinnitus, anterior uveitis Ophthalmology referral. MH follow-up. Review at 1 y: 
improvement in tinnitus, now occasional 
19 38/M Undifferentiated headache Local MH follow-up 
20 30/F Resolved migraine headache Review at 1 y: new onset headache with cluster-type 
features 
21 32/F Migraine headache, right eye cataract, tinnitus Ophthalmology referral 
22 21/F Migraine headache, tinnitus Propranolol 20 mg/d. Headache improved from 8/10 to 
4/10. Review at 1 y: no further headache 
23 46/M Essential tremor, undifferentiated headache DNA specialist clinic 
24 43/F Migraine headache Propranolol 20 mg/d, initially 10/10 headache pain now 
better (not able to quantify). Review at 1 y: decreased 
frequency of headaches, now occasional 
25 42/M Extensive right MCA infarct, major depressive disorder Physiotherapy, MH follow-up. Review at 1 y: 
improvement in symptoms. Patient subsequently died. 
26 25/F Ulnar nerve palsy DNA specialist clinic 
27 25/M Migraine headache, asymmetric lower limb muscle 
wasting 
MH follow-up. Review at 1 y: decreased frequency of 
headaches, now occasional 
28 21/F Tension-type headache Review at 1 y: decreased frequency of headaches; now 
occasional. Fever/rash during pregnancy; miscarriage  
29 61/F Migraine headache, bilateral cataract Local MH follow-up 
30 19/F Anterior uveitis, undifferentiated headache Urgent referral to local ophthalmology clinic 
31 33/F Migraine headache, generalized anxiety disorder Propranolol 20 m/d; improved headache from 10/10 to 
6/10. MH follow-up 
32 43/F Undifferentiated headache, arthralgia Referred to local ophthalmology clinic 
33 41/F Migraine headache, anxiety MH follow-up, simple analgesia. Review at 1 y: 
decreased frequency of headaches, now occasional 
34 25/F Undifferentiated headache Referred to general survivor’s clinic 
35 35/M Migraine headache, asymmetric sensory peripheral 
neuropathy, major depressive disorder 
MH follow-up, propranolol 20 mg/d, gabapentin 300 mg 
each night, diet advice and review in diabetic clinic 
referral. Headache improved (unable to quantify); pain in 
feet improved. Review at 1 y: decreased frequency of 
headaches, now occasional; improvement in neuropathy 
37 12/F Severe neurocognitive impairment, postviral encephalitis Referral to orphanage for 24-h care 
38 21/M Undifferentiated headache, arthralgia ND 
*MH, mental health; MCA, middle cerebral artery; ND, no data.  
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Table 3. Demographics, clinical characteristics during acute admission, and cycle threshold of preliminary clinic group in study of 
severe neurologic sequelae among Ebola virus disease survivors, by those who had severe and those who had no severe 
neurologic conditions, Sierre Leone* 
Characteristic 
No severe neurologic 
features, n = 21 
Severe neurologic 
features, n = 19 
Crude odds 
ratio† 95% CI 
Age, y, median (IQR) 28 (23–60) 32 (25–42) 0.01/y 0.00–0.036 
Female sex, % (95% CI) 48 (43–54) 68 43–87 2.3 0.79–7.60 
Length of stay, d, median (IQR) 18 (14–28) 25 (13–29) 0.02/d   
Seizures during admission, % (95% CI) 19 (5–42) 21 (6–46) 1.13 0.18–7.23 
Unconscious during admission, % (95% CI) 33 (15–57) 63 (38–83) 3.32 0.79–15.4 
Bleeding during admission, % (95% CI) 19 5–42 5 (0.1–26) 0.24 0.00–2.80 
Cycle threshold, median (IQR) 22.8 (22.1–24.1), n = 9 27.2 (22.5–30.1), n = 10 0.22 for each 
increment 
0.7–1.3 
*Severe conditions were those requiring specialist referral. 
†Odds ratio of patients having severe neurologic features to those who did not. 
 
 
Figure 1. Flowchart showing clinic referral process from initial patient cohort to preliminary clinic and then 
specialist clinics in study of severe neurologic sequelae among Ebola virus disease survivors, Sierre 
Leone. Criteria for selection for preliminary clinic assessement from the 34 Military Hospital/University of 
Liverpool cohort were presence >1 major or >2 minor symptoms (see Table 1) or nurse-led selection on 
the basis of symptoms. CT, computed tomography. 
Figure 2. Prevalence of neurological symptoms by sex in study of severe neurologic sequelae among 
Ebola virus disease survivors, Sierre Leone. Cohort consisted of 24 survivors attending the 34 Military 
Hospital /University of Liverpool survivors clinic. Eerror bars indicate 95% CI. 
Figure 3. Representative nonenhanced computed tomography (CT) brain scans and composite scanning 
laser ophthalmoscope fundus images of 2 Ebola virus disease survivors attending a joint neurologic and 
psychiatric clinic in Sierre Leone. A) Patient no. 37, female, age 12. CT of brain shows disproportionate 
parietal and temporal lobe atrophy. B) Patient no. 25, male, age 42. CT of brain shows extensive gliosis 
within the left MCA territory reflects an old infarct with ex-vacuo dilatation of left lateral ventricle due to 
hemispheric volume loss. C) Patient no. 12, age 40. Retinal imaging shows left and right eye, with 
extensive bilateral peripapillary pale retinal lesions with pigmentation of larger lesions. Lesions appear to 
spare the fovea. Visual acuity was 20/25 (right) and 20/20 (left) (24). D) Patient no.  25, male, age 42. 
Retinal imaging shows left and right eye, with peripapillary pale retinal lesions. Visual acuity was 20/25 
both eyes (25). 
34 Military/University of Liverpool 
Survivor cohort (n= 361)
Invited for neurology and psychiatric 
screening clinic 
(n=111)
5 not included as incomplete data 
22 not included as < 12 years old 
223 not included as did not meet selection 
criteria
Attended neurological and psychiatric 
preliminary clinic 
(n=40)
- 64 not contactable*
- 7 contactable but did not attend 
clinic
Offered joint neurological and 
psychiatric specialist clinic 
appointment and CT brain scanning
(n=19)
Attended joint Neurology and 
Psychiatry specialist clinic (n=15)
Attended Psychiatry clinic only (n=4)
Completed CT scan (n=17)
* Either due to phone number not being available, or phone repeatedly being switched off 
- 4 did not attend joint Neurology 
and Psychiatry specialist clinic 
- 2 did not attend Psychiatry clinic 
only 
- 1 did not attend CT scan, 1 
pregnant
Sierra Leone Survivor Cohort 
(n=10,168)
Confirmed primary neurological or 
psychiatric diagnosis
(n=34)
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